Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

Cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade with a monoclonal antibody yields durable responses in a subset of cancer patients and has been approved by the FDA as a standard therapy for late-stage melanoma. We recently identified inducible co-stimulator (ICOS) as a crucial player in the antit...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Xiaozhou, Quezada, Sergio A., Sepulveda, Manuel A., Sharma, Padmanee, Allison, James P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978270/
https://www.ncbi.nlm.nih.gov/pubmed/24687957
http://dx.doi.org/10.1084/jem.20130590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978270/
https://www.ncbi.nlm.nih.gov/pubmed/24687957
http://dx.doi.org/10.1084/jem.20130590

Ejemplares similares